<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544060</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 304801</org_study_id>
    <nct_id>NCT03544060</nct_id>
  </id_info>
  <brief_title>Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)</brief_title>
  <official_title>Volanesorsen (ISIS 304801) Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CaligorRx, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this program is to provide expanded access to volanesorsen for up to 100
      Patients with Familial Chylomicronemia Syndrome (FCS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Program is intended to provide expanded access to volanesorsen for eligible patients with
      FCS who have limited or no available treatment options.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Familial Chylomicronemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volanesorsen</intervention_name>
    <description>Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.</description>
    <other_name>Waylivra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who participated in the APPROACH Open Label trial, must have completed the
             open label extension trial for volanesorsen for a length of time consistent with the
             study protocol (≥ 1 year). Patients in the APPROACH open Label trial for less than a
             year require approval from Akcea to participate in the EAP. Patients who did not
             participate in the APPROACH open label trial require approval from Akcea for entry
             into EAP.

          -  Patients not participating in the APPROACH open label trial must have a diagnosis of
             FCS as determined by the participating physician, as outlined in the Volanesorsen EAP
             protocol. Akcea will review each application to determine eligibility.

          -  Male patients and female patients of childbearing potential must continue to use
             appropriate contraception with their partners, or refrain from sexual activity

        Exclusion Criteria:

          -  Patients who have any new conditions or worsening of existing conditions which in the
             opinion of the Physician would make the patient unsuitable for treatment with
             volanesorsen.

          -  Volanesorsen naïve patients with baseline platelet values ≤ 140,000/mm3

          -  Patients not willing to adhere to mandatory blood draws for platelet monitoring

          -  Patients who in the opinion of Akcea's medical team, are not eligible candidates for
             volanesorsen therapy.

          -  Any patient who plans to or becomes pregnant.

          -  Any patient who was withdrawn from the APPROACH open label study due to a serious
             adverse event related to volanesorsen therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Akcea Therapeutics</last_name>
    <phone>617-207-0289</phone>
    <email>clinicalstudies@akceatx.com</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Chylomicronemia</keyword>
  <keyword>Familial Lipoprotein Lipase Deficiency</keyword>
  <keyword>Hyperlipoproteinemias</keyword>
  <keyword>Familial Hyperlipoproteinemia Type 1</keyword>
  <keyword>Hyperlipoproteinemia Type 1</keyword>
  <keyword>Hyperchylomicronemia, Familial</keyword>
  <keyword>Lipoprotein Lipase Deficiency, Familial</keyword>
  <keyword>Hyperlipidemias</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Lipid Metabolism, Inborn Errors</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

